Sonoma Pharmaceuticals, Inc.

Sonoma Pharmaceuticals develops and manufactures stabilized hypochlorous acid (HOCl) products for topical wound care, dermatology, ophthalmology, and other therapeutic applications. The company's core technology platform centers on HOCl-based formulations that target microbial pathogens and support tissue healing. Its portfolio spans multiple therapeutic areas and customer segments, including human healthcare, veterinary medicine, and institutional/hospital use.

The company's human healthcare products include Regenacyn (prescription scar gel), Levicyn (wound care), Microcyn (antimicrobial topical line), Reliefacyn (dermatological conditions), and specialized formulations for oral care (Microdacyn60), eye care (Ocucyn, Ocudox), nasal irrigation (Sinudox), and podiatry (Podiacyn). Veterinary offerings include MicrocynAH and MicrocynVS for animal skin conditions. The company also produces institutional products such as Nanocyn (hospital-grade disinfectant) and Endocyn (endodontic irrigation solution).

Sonoma Pharmaceuticals operates with a minimal employee base of eight full-time staff and maintains headquarters in Boulder, Colorado. The company distributes products across North America, Europe, Asia, and Latin America through various distribution channels. Incorporated in Delaware in 1999 and formerly known as Oculus Innovative Sciences, the company changed its name in December 2016 and is publicly traded on Nasdaq.